Latest California Healthline Stories
Proposition 65 requires California businesses to label products and buildings with warnings about substances the state deems as toxic, ranging from aloe vera to asbestos. A state panel plans to debate whether to add acetaminophen, the active ingredient of common over-the-counter medications such as Tylenol, to the toxics list, raising questions about the value of these ubiquitous warnings.
Legislation that takes effect next July will let people buy the medications without a prescription for a limited period. Medical professionals say it’s a step in the right direction but will not significantly increase the use of the medicine without additional efforts.
The final directive drew swift responses from the hospital and insurance industries. The Trump administration also released a proposed rule that would require health insurers to spell out for all services beforehand just how much patients may owe for their out-of-pocket costs.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
It’s November, do you know where your HHS spending bill is? Still stuck in Congress. Meanwhile, lawmakers move ahead on restricting tobacco products for youth while the administration’s proposal is MIA. Rebecca Adams of CQ Roll Call and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss this and more health news from the week. Also, Rovner interviews Dan Weissmann, host of the podcast “An Arm and a Leg.”
Nearly 8 in 10 Americans say the cost of prescription drugs is unreasonable, but the odds look grim for Congress to pass significant pricing legislation this year.
Doctors are less likely to prescribe opioids in Germany and quicker to notice if a patient is at risk of abuse. And, for those who do experience addiction, treatment is easier to come by.
Kaiser Health News’ Shefali Luthra discusses the recent Trump administration lawsuit regarding the HIV-prevention drug Truvada.
The agency approved Gilead’s “game changer” hepatitis C cure, bypassing concerns raised by its own federal inspectors. The problems they found at the company’s main U.S. drug-testing laboratory in Foster City, Calif., were so bad, they recommended withholding approval.
A few hundred hospitals have banded together to sue drugmakers in state courts, but far more are staying on the sidelines to avoid ‘unflattering attention’ about their role in the opioid crisis.